KORU Medical (KRMD) - Pangali EV/EBITDA

KORU Medical Systems (KRMD) generates revenue by creating subcutaneous infusion systems, where high pump assembly automation and the mass production of consumables significantly increase profits. The market value dynamics of the asset, recorded at 0.00, confirm the effectiveness of the strategy. The Freedom ecosystem ensures comfort in treating immunodeficiency, creating sustainable patient brand loyalty through the integration of devices and ancillary materials.

To objectively compare assets, an investor must evaluate business value accounting for net debt. This multiple compares the total enterprise value with its operating profit before depreciation and taxes. Regulatory delay risks for KORU Medical Systems (KRMD) could reduce EBITDA, leading to a sharp increase in the company's valuation multiple. By analyzing the EV/EBITDA dynamics of the business, one can timely detect the threat of capital impairment.